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OARSI guidelines for hip and knee OA: deciphering
the topical drug me´langeI am confused by the evidence for topical non-steroidal anti-
inﬂammatory drugs (NSAIDs) to treat knee osteoarthritis
(OA) pain, presented by Zhang et al.1, in General Recom-
mendation 15, ‘‘Topical NSAIDs and capsaicin.’’, of the
new OARSI guidelines. Given the authors’ widely-supported
preference for evidence-based conclusions derived wher-
ever possible from randomized controlled trials (RCTs), it
is surprising that they too grouped these two very different
pharmaceutical substances and assigned them the same
level (LoE) and strength of evidence rating (SOR), citing dif-
ferent quantity and quality of published data for each and
noting that ‘‘adequate blinding is not possible in trials with
this agent [capsaicin]’’.
Indeed, lumping all topical NSAID products together in-
troduces further questions, on both basic science and clin-
ical grounds. One must take into account that the many and
varied topical NSAID preparations differ not only in the ac-
tive medication being delivered, each with its own biochem-
ical properties, but also in the components of the vehicle,
the nature of the formulation (lotion, gel, solution, patch,
etc.) and the presence of penetration enhancers used to de-
liver the drug across the skin2,3. The key meta-analysis by
Lin et al.3 detailed here and cited in Part I of the recommen-
dations4 as evidence supportive of OARSI Recommenda-
tion 15 noted ‘‘some heterogeneity of efﬁcacy between
preparations’’. The authors concluded that ‘‘the beneﬁt
may be drug speciﬁc rather than class speciﬁc’’. Moreover,
in critically assessing the merit of the limited 2-week data
that did show an effect and more relevant 4-week data
showing no effect, Lin et al. opined, ‘‘In conclusion, re-
search evidence to support the long-term use (more than
one month) of topical NSAIDs in osteoarthritis is absent.
Current recommendations that support their use in osteoar-
thritis need to be revised’’; hardly a basis for the Ia level of
evidence recommendation (Table 1)1.
Recommendation 15 may have relied on the more recent
meta-analysis by Biswal et al.5 favouring topical NSAIDs.
Focussing on RCTs of at least 4 weeks duration the
authors identiﬁed only four satisfactory citations e two neg-
ative trials evaluating an eltenac gel that had been included
in previous meta-analyses3 and two more recent publica-
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1586Nuvo Research Inc.). Biswal et al. also concluded that
‘‘this ﬁnding [efﬁcacy of topical NSAIDs] may not hold
true for all the preparations’’. One anticipates that subse-
quent updates of these recommendations will include ap-
praisal of ﬁve newer publications discussing Pennsaid
(two more RCTs6,7, one meta-analysis8 and two guide-
lines9,10) that appeared after the OARSI review cut-off
date of January 31, 2006. These peer-reviewed publica-
tions add further replicate RCT data demonstrating that at
least this formulation has long-term efﬁcacy and safety. In
particular, the rigorous 12-week non-inferiority trial with
oral diclofenac (not just an effect size comparison) strongly
supports Pennsaid as an ‘‘alternative to oral analgesic/anti-
inﬂammatory agents in knee OA’’1. While this evidence
does inform the OARSI recommendation, for at least this
topical NSAID product, we hope that differences among
topical NSAIDs derived from published data will receive
full discussion as an addendum to the current recommen-
dations and in the ﬁrst revision.
Sincerely,J. Zev Shainhouse M.D., B.Sc., F.R.C.P.C.*
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